Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Surg Pathol. 2014 Jan;38(1):86-93. doi: 10.1097/PAS.0b013e3182a43996.

Assessment of SOX11 expression in routine lymphoma tissue sections: characterization of new monoclonal antibodies for diagnosis of mantle cell lymphoma.

Author information

1
*Hematopathology Unit, Pathology Department, Hospital Clínic ‡Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) §Department of Anatomic Pathology, Pharmacology and Microbiology, University of Barcelona, Barcelona, Spain †Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland ∥Research and Development, Atlas Antibodies, Stockholm, Sweden.

Abstract

The diagnosis of mantle cell lymphoma (MCL) can be difficult, especially when no t(11;14) translocation and cyclin D1 overexpression can be detected. In such cases, the transcription factor SOX11 represents an important diagnostic marker, as it is expressed in most MCLs and, in particular, in all cyclin D1-negative MCLs reported so far. A reliable anti-SOX11 antibody is therefore a very useful tool for routine diagnosis. Here, we characterize the new monoclonal anti-SOX11 antibodies, suitable for Western blot assay and immunohistochemistry (IHC) on formalin-fixed paraffin-embedded tissue; we tested them on a large series of primary lymphoid tumors and compared these results with those of other routinely used antibodies. Moreover, we show that IHC results depend on transcription levels of SOX11, which suggests that posttranscriptional and posttranslational modifications do not significantly affect cutoff levels for IHC detection of SOX11.

PMID:
24145648
DOI:
10.1097/PAS.0b013e3182a43996
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Support Center